Antithrombotic management in atrial fibrillation patients following percutaneous coronary intervention: A clinical review
Y Saito, Y Kobayashi - Journal of Arrhythmia, 2024 - Wiley Online Library
Patients with atrial fibrillation (AF) often develop acute coronary syndrome and undergo
percutaneous coronary intervention (PCI), and vice versa. Acute coronary syndrome and …
percutaneous coronary intervention (PCI), and vice versa. Acute coronary syndrome and …
One-Month Dual Antiplatelet Therapy Followed by P2Y12 Inhibitor Monotherapy After Biodegradable Polymer Drug-Eluting Stent Implantation―The REIWA Region …
M Ishida, R Shimada, F Takahashi, M Niiyama… - Circulation …, 2024 - jstage.jst.go.jp
Background: The safety and feasibility of using 1-month dual antiplatelet therapy (DAPT)
followed by P2Y 12 inhibitor monotherapy for patients after percutaneous coronary …
followed by P2Y 12 inhibitor monotherapy for patients after percutaneous coronary …
Clopidogrel induced reduction in neutrophil count: An overlooked beneficial effect?
S De Servi, A Landi, S Savonitto - European Journal of Internal Medicine, 2024 - Elsevier
Complement-stimulated neutrophils are able to adhere to the endothelium and damage
endothelial cells both in vitro and in vivo. These blood cells participate in the early stages …
endothelial cells both in vitro and in vivo. These blood cells participate in the early stages …
Monotherapy with P2Y12-inhibitors after dual antiplatelet therapy: Filling gaps in evidence
G Andò, L Lombardo, G Alagna, A Micari… - International Journal of …, 2024 - Elsevier
Abstract Background Whether P2Y 12 inhibitor monotherapy (P2Y 12-I) is superior to aspirin
following DAPT discontinuation post-PCI remains to be established. Methods We updated …
following DAPT discontinuation post-PCI remains to be established. Methods We updated …
Clopidogrel for Long-Term Secondary Prevention After Coronary Artery Stenting
A Bellemain-Appaix, G Montalescot - Journal of the American College of …, 2024 - jacc.org
Balancing ischemic and bleeding risk after drug-eluting stent (DES) coronary implantation is
an ongoing challenge. Both the prevention of ischemic and bleeding events are critical …
an ongoing challenge. Both the prevention of ischemic and bleeding events are critical …